7.1 USP <795>/<797> Interface for Hazardous Drugs

USP <795>/<797> Interface for Hazardous Drugs

On the PTCB Hazardous Drug Management exam, USP <800> is easy to mistake for a stand-alone rulebook — as if hazardous drugs lived in their own separate compounding universe. They don't. USP <800> is an overlay chapter: it adds hazardous-drug containment and PPE requirements on top of whichever base compounding-quality chapter already governs the dosage form being prepared. Questions in the Dispensing Final Dosage Forms domain frequently test whether you understand this interface — which standard applies, and whether it applies instead of or in addition to another.

Why the Interface Exists

USP <795> and USP <797> exist independently of hazardous-drug status. They set the baseline quality bar for any compounded preparation — nonsterile or sterile — because a patient needs a correctly formulated, correctly dated, uncontaminated product no matter what the active ingredient is. USP <800> was written afterward, specifically to address occupational exposure risk for the personnel preparing and handling those preparations. Rather than duplicating <795>'s or <797>'s facility and technique requirements, USP <800> was designed to reference and add to them. That is why exam questions about this interface work as a two-step lookup instead of a single merged chapter.

Three Chapters, Three Jobs

The critical exam point: <800> does not replace <795> or <797>. A hazardous sterile admixture must satisfy the sterile compounding standards of <797> and the containment requirements of <800> at the same time — neither chapter substitutes for the other.

Two Questions That Decide Which Standard Applies

Before answering a dispensing-interface question, work through two things in order:

1. Is the final product sterile or nonsterile? This determines whether <795> or <797> is the base standard.
2. Does the activity involve compounding or manipulation, or is it only counting, weighing, or repackaging an already-finished dosage form? This determines whether the Assessment of Risk (AoR) pathway, covered in Chapter 1, is even available for the task. An AoR is eligible only for final dosage forms that require no manipulation. Reconstituting, mixing, diluting, splitting, crushing, or otherwise altering the dosage form is compounding, and compounding always pulls the task into full <795>/<797> territory.

Worked Contrast: Same Drug Class, Three Different Answers

Counting whole tablets. A technician counts intact tamoxifen 20 mg tablets from a manufacturer's stock bottle into a dispensing vial for a 30-day prescription. Nothing about the tablet is altered, so no compounding occurs — this task is a candidate for the AoR pathway rather than full <795> facility requirements, though the technician still wears single chemotherapy-rated gloves as the <800> floor.

Compounding a nonsterile suspension. A caregiver needs a liquid form of methotrexate for a patient who cannot swallow tablets. Turning tablets into a suspension is manipulation, not counting. Full USP <795> quality standards apply — a dedicated nonsterile compounding area, a documented formulation and BUD, trained personnel — and USP <800> containment requirements (dedicated HD-only equipment, chemo PPE, a contained compounding space) apply on top.

Reconstituting a sterile admixture. A technician reconstitutes a NIOSH-listed antineoplastic injectable for infusion. This is sterile compounding, so USP <797>'s environmental monitoring, ISO classification, and BUD standards apply as the base layer. Because the drug is hazardous, USP <800> adds its own requirement that the work happen inside a certified containment primary engineering control (a Class II BSC or a CACI), using a closed system transfer device (CSTD) where the dosage form allows, with full chemotherapy-rated PPE.

Decision Matrix

Common Exam Traps

Two mirror-image mistakes show up repeatedly on this topic:

• “Oral means <800> doesn't apply.” Wrong — an oral final dosage form on the NIOSH list still triggers <800>'s containment/PPE floor, and if it requires compounding, it triggers full <795> as well.
• “<800> is the whole rulebook.” Also wrong — <800> never stands alone. It cannot be satisfied by PPE and engineering controls if the underlying activity is compounding; the base <795> or <797> quality standards (facility, documentation, BUD, technique) must still be met.

Keep both directions in mind on exam day: <800> is additive, and the sterile/nonsterile split under <795>/<797> never disappears just because a drug happens to be hazardous.